CG Oncology, Inc.
CGON- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001991792
In the last 90 days, CG Oncology, Inc. insiders filed 0 open-market purchases and 4 sales; 227 institutions reported holding it in 13F filings for Q2 2026, worth $6.66B in total; no superinvestor holds it.
Holders of 5% or more of CGON
Holders whose latest Schedule 13D or 13G filing reports 5% or more of CG Oncology, Inc., largest stake first. The change is against the holder's previous filing.
| Holder | Latest form | Stake | Change | First filed | Latest filing | Filing |
|---|---|---|---|---|---|---|
| Decheng Capital Global Life Sciences Fund IV, L.P. | 13G/A | 8.40%6.37M shares | – | Feb 14, 20251 filing | Feb 14, 2025 | SEC |
| Wellington Management Group LLP | 13G | 7.20%5.51M shares | New | Nov 12, 20251 filing | Nov 12, 2025 | SEC |
| Longitude Capital Partners IV, LLC | 13D | 6.00%4.66M shares | New | Sep 18, 20251 filing | Sep 18, 2025 | SEC |
| Unique Diamond Investments Ltd | 13G/A | 5.50%4.21M shares | – | Jan 28, 20251 filing | Jan 28, 2025 | SEC |
| FMR LLC | 13G | 5.10%3.86M shares | New | Aug 6, 20251 filing | Aug 6, 2025 | SEC |
Stakes are as of each holder's latest filing. Holders whose last filing was in the old format (before December 18, 2024) have no stake on record and are not listed, and after an acquisition or delisting holders usually stop filing.
13D and 13G filings
10 Schedule 13D and 13G filings on CG Oncology, Inc., newest first, including old-format filings without a stake.
| Filed (ET) | Filer | Form | Stake | Change | Event date | Filing |
|---|---|---|---|---|---|---|
| Mar 26, 20265:13 PM ET | Vanguard Group Inc | 13G/A | 0.00%0 shares | −8.62 ppfrom 8.62%Below 5% | Mar 13, 2026 | SEC |
| Nov 12, 20259:33 AM ET | Wellington Management Group LLPand 3 others | 13G | 7.20%5.51M shares | New | Sep 30, 2025 | SEC |
| Oct 30, 20252:54 PM ET | Vanguard Group Inc | 13G/A | 8.62%6.58M shares | – | Sep 30, 2025 | SEC |
| Oct 28, 20255:12 PM ET | Seven Fleet Capital Management LPand 3 others | 13D/A | 2.00%1.54M shares | –Below 5% | Oct 6, 2025 | SEC |
| Sep 18, 20258:37 PM ET | Longitude Capital Partners IV, LLCand 5 others | 13D | 6.00%4.66M shares | New | Sep 11, 2025 | SEC |
| Sep 18, 20258:22 PM ET | Seven Fleet Partners LPand 2 others | 13D | 2.00%1.52M shares | NewBelow 5% | Sep 11, 2025 | SEC |
| Aug 6, 202511:56 AM ET | FMR LLCand 1 other | 13G | 5.10%3.86M shares | New | Jun 30, 2025 | SEC |
| May 15, 20254:32 PM ET | TCG Crossover GP I, LLCand 2 others | 13G/A | 4.80%3.67M shares | –Below 5% | Mar 31, 2025 | SEC |
| Feb 14, 20255:40 PM ET | Decheng Capital Global Life Sciences Fund IV, L.P.and 4 others | 13G/A | 8.40%6.37M shares | – | Dec 31, 2024 | SEC |
| Jan 28, 20255:08 PM ET | Unique Diamond Investments Ltdand 9 others | 13G/A | 5.50%4.21M shares | – | Dec 31, 2024 | SEC |
Form 144: proposed insider sales
Notices from officers, directors and other affiliates planning to sell CG Oncology, Inc. shares.
No Form 144 notices for CG Oncology, Inc. are on file.